CD274 and neoplasm: To this regard, patients enrolled in the MiST trial (NCT03654833) are currently offered a specific study treatment (either the parp-inhibitor rucaparib, the CDK4/6 inhibitor abemaciclib, the combination of the PD-1 inhibitor pembrolizumab and the AXL inhibitor bemcentinib or the combination of the PD-L1 inhibitor atezolizumab and the anti-angiogenic agent bevacizumab) determined by the results of the molecular panel testing of their diagnostic tumor block.